Individual risk of cutaneous melanoma in New Zealand: developing a clinical prediction aid

New Zealand and Australia have the highest melanoma incidence rates worldwide. In New Zealand, both the incidence and thickness have been increasing. Clinical decisions require accurate risk prediction but a simple list of genetic, phenotypic and behavioural risk factors is inadequate to estimate in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC cancer 2014-05, Vol.14 (1), p.359-359, Article 359
Hauptverfasser: Sneyd, Mary Jane, Cameron, Claire, Cox, Brian
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 359
container_issue 1
container_start_page 359
container_title BMC cancer
container_volume 14
creator Sneyd, Mary Jane
Cameron, Claire
Cox, Brian
description New Zealand and Australia have the highest melanoma incidence rates worldwide. In New Zealand, both the incidence and thickness have been increasing. Clinical decisions require accurate risk prediction but a simple list of genetic, phenotypic and behavioural risk factors is inadequate to estimate individual risk as the risk factors for melanoma have complex interactions. In order to offer tailored clinical management strategies, we developed a New Zealand prediction model to estimate individual 5-year absolute risk of melanoma. A population-based case-control study (368 cases and 270 controls) of melanoma risk factors provided estimates of relative risks for fair-skinned New Zealanders aged 20-79 years. Model selection techniques and multivariate logistic regression were used to determine the important predictors. The relative risks for predictors were combined with baseline melanoma incidence rates and non-melanoma mortality rates to calculate individual probabilities of developing melanoma within 5 years. For women, the best model included skin colour, number of moles > =5 mm on the right arm, having a 1st degree relative with large moles, and a personal history of non-melanoma skin cancer (NMSC). The model correctly classified 68% of participants; the C-statistic was 0.74. For men, the best model included age, place of occupation up to age 18 years, number of moles > =5 mm on the right arm, birthplace, and a history of NMSC. The model correctly classified 67% of cases; the C-statistic was 0.71. We have developed the first New Zealand risk prediction model that calculates individual absolute 5-year risk of melanoma. This model will aid physicians to identify individuals at high risk, allowing them to individually target surveillance and other management strategies, and thereby reduce the high melanoma burden in New Zealand.
doi_str_mv 10.1186/1471-2407-14-359
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4038363</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1532939774</sourcerecordid><originalsourceid>FETCH-LOGICAL-b484t-ad6ae472233d0c870c000f301c0148c3445f213da18fe6a26cc1b0ffe6fe0ee93</originalsourceid><addsrcrecordid>eNp1kUFv1DAQhS0EomXhzglZ4sIlMBM7icMBCa0oVKrgApdeLK89KS6JvdjJIv59vdqyahGc_DTz_PT0DWPPEV4jqvYNyg6rWkJXoaxE0z9gp8fRwzv6hD3J-RoAOwXqMTuppVJSYn_KLs-D8zvvFjPy5PMPHgdul9kEikvmE40mxMlwH_hn-sUvyZSBe8sd7WiMWx-uuOF29MHbErBN5LydfQzcePeUPRrMmOnZ7bti384-fF1_qi6-fDxfv7-oNlLJuTKuNSS7uhbCgVUdWAAYBKAFlMoKKZuhRuEMqoFaU7fW4gaGogcCol6s2LtD7nbZTOQshTmZUW-Tn0z6raPx-v4m-O_6Ku60BKFEK0rA-hCw8fE_Afc3Nk56z1bv2RalC_qS8uq2Roo_F8qznny2NI4HlhobUfei7zpZrC__sl7HJYUCae_qEJum4FgxOLhsijknGo6NEPT-_P_q8OIuiuOHP_cWN24Lq-s</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1537115522</pqid></control><display><type>article</type><title>Individual risk of cutaneous melanoma in New Zealand: developing a clinical prediction aid</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>SpringerLink Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><creator>Sneyd, Mary Jane ; Cameron, Claire ; Cox, Brian</creator><creatorcontrib>Sneyd, Mary Jane ; Cameron, Claire ; Cox, Brian</creatorcontrib><description>New Zealand and Australia have the highest melanoma incidence rates worldwide. In New Zealand, both the incidence and thickness have been increasing. Clinical decisions require accurate risk prediction but a simple list of genetic, phenotypic and behavioural risk factors is inadequate to estimate individual risk as the risk factors for melanoma have complex interactions. In order to offer tailored clinical management strategies, we developed a New Zealand prediction model to estimate individual 5-year absolute risk of melanoma. A population-based case-control study (368 cases and 270 controls) of melanoma risk factors provided estimates of relative risks for fair-skinned New Zealanders aged 20-79 years. Model selection techniques and multivariate logistic regression were used to determine the important predictors. The relative risks for predictors were combined with baseline melanoma incidence rates and non-melanoma mortality rates to calculate individual probabilities of developing melanoma within 5 years. For women, the best model included skin colour, number of moles &gt; =5 mm on the right arm, having a 1st degree relative with large moles, and a personal history of non-melanoma skin cancer (NMSC). The model correctly classified 68% of participants; the C-statistic was 0.74. For men, the best model included age, place of occupation up to age 18 years, number of moles &gt; =5 mm on the right arm, birthplace, and a history of NMSC. The model correctly classified 67% of cases; the C-statistic was 0.71. We have developed the first New Zealand risk prediction model that calculates individual absolute 5-year risk of melanoma. This model will aid physicians to identify individuals at high risk, allowing them to individually target surveillance and other management strategies, and thereby reduce the high melanoma burden in New Zealand.</description><identifier>ISSN: 1471-2407</identifier><identifier>EISSN: 1471-2407</identifier><identifier>DOI: 10.1186/1471-2407-14-359</identifier><identifier>PMID: 24884419</identifier><language>eng</language><publisher>England: BioMed Central</publisher><subject>Adult ; Aged ; Case-Control Studies ; Chi-Square Distribution ; Decision Support Techniques ; Epidemiology ; Ethics ; Female ; Genetic Predisposition to Disease ; Genotype &amp; phenotype ; Humans ; Incidence ; Interviews ; Laboratories ; Logistic Models ; Male ; Medicine ; Melanoma ; Melanoma - diagnosis ; Melanoma - epidemiology ; Melanoma - genetics ; Middle Aged ; Missing data ; Mortality ; Multivariate Analysis ; Nevus - diagnosis ; Nevus - epidemiology ; Nevus - genetics ; New Zealand - epidemiology ; Population ; Predictive Value of Tests ; Prevention ; Residence Characteristics ; Risk Assessment ; Risk Factors ; Scandals ; Sex Factors ; Skin cancer ; Skin Neoplasms - diagnosis ; Skin Neoplasms - epidemiology ; Skin Neoplasms - genetics ; Skin Pigmentation ; Time Factors ; Variables ; Women ; Workplace ; Young Adult</subject><ispartof>BMC cancer, 2014-05, Vol.14 (1), p.359-359, Article 359</ispartof><rights>2014 Sneyd et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.</rights><rights>Copyright © 2014 Sneyd et al.; licensee BioMed Central Ltd. 2014 Sneyd et al.; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b484t-ad6ae472233d0c870c000f301c0148c3445f213da18fe6a26cc1b0ffe6fe0ee93</citedby><cites>FETCH-LOGICAL-b484t-ad6ae472233d0c870c000f301c0148c3445f213da18fe6a26cc1b0ffe6fe0ee93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4038363/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4038363/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24884419$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sneyd, Mary Jane</creatorcontrib><creatorcontrib>Cameron, Claire</creatorcontrib><creatorcontrib>Cox, Brian</creatorcontrib><title>Individual risk of cutaneous melanoma in New Zealand: developing a clinical prediction aid</title><title>BMC cancer</title><addtitle>BMC Cancer</addtitle><description>New Zealand and Australia have the highest melanoma incidence rates worldwide. In New Zealand, both the incidence and thickness have been increasing. Clinical decisions require accurate risk prediction but a simple list of genetic, phenotypic and behavioural risk factors is inadequate to estimate individual risk as the risk factors for melanoma have complex interactions. In order to offer tailored clinical management strategies, we developed a New Zealand prediction model to estimate individual 5-year absolute risk of melanoma. A population-based case-control study (368 cases and 270 controls) of melanoma risk factors provided estimates of relative risks for fair-skinned New Zealanders aged 20-79 years. Model selection techniques and multivariate logistic regression were used to determine the important predictors. The relative risks for predictors were combined with baseline melanoma incidence rates and non-melanoma mortality rates to calculate individual probabilities of developing melanoma within 5 years. For women, the best model included skin colour, number of moles &gt; =5 mm on the right arm, having a 1st degree relative with large moles, and a personal history of non-melanoma skin cancer (NMSC). The model correctly classified 68% of participants; the C-statistic was 0.74. For men, the best model included age, place of occupation up to age 18 years, number of moles &gt; =5 mm on the right arm, birthplace, and a history of NMSC. The model correctly classified 67% of cases; the C-statistic was 0.71. We have developed the first New Zealand risk prediction model that calculates individual absolute 5-year risk of melanoma. This model will aid physicians to identify individuals at high risk, allowing them to individually target surveillance and other management strategies, and thereby reduce the high melanoma burden in New Zealand.</description><subject>Adult</subject><subject>Aged</subject><subject>Case-Control Studies</subject><subject>Chi-Square Distribution</subject><subject>Decision Support Techniques</subject><subject>Epidemiology</subject><subject>Ethics</subject><subject>Female</subject><subject>Genetic Predisposition to Disease</subject><subject>Genotype &amp; phenotype</subject><subject>Humans</subject><subject>Incidence</subject><subject>Interviews</subject><subject>Laboratories</subject><subject>Logistic Models</subject><subject>Male</subject><subject>Medicine</subject><subject>Melanoma</subject><subject>Melanoma - diagnosis</subject><subject>Melanoma - epidemiology</subject><subject>Melanoma - genetics</subject><subject>Middle Aged</subject><subject>Missing data</subject><subject>Mortality</subject><subject>Multivariate Analysis</subject><subject>Nevus - diagnosis</subject><subject>Nevus - epidemiology</subject><subject>Nevus - genetics</subject><subject>New Zealand - epidemiology</subject><subject>Population</subject><subject>Predictive Value of Tests</subject><subject>Prevention</subject><subject>Residence Characteristics</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Scandals</subject><subject>Sex Factors</subject><subject>Skin cancer</subject><subject>Skin Neoplasms - diagnosis</subject><subject>Skin Neoplasms - epidemiology</subject><subject>Skin Neoplasms - genetics</subject><subject>Skin Pigmentation</subject><subject>Time Factors</subject><subject>Variables</subject><subject>Women</subject><subject>Workplace</subject><subject>Young Adult</subject><issn>1471-2407</issn><issn>1471-2407</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kUFv1DAQhS0EomXhzglZ4sIlMBM7icMBCa0oVKrgApdeLK89KS6JvdjJIv59vdqyahGc_DTz_PT0DWPPEV4jqvYNyg6rWkJXoaxE0z9gp8fRwzv6hD3J-RoAOwXqMTuppVJSYn_KLs-D8zvvFjPy5PMPHgdul9kEikvmE40mxMlwH_hn-sUvyZSBe8sd7WiMWx-uuOF29MHbErBN5LydfQzcePeUPRrMmOnZ7bti384-fF1_qi6-fDxfv7-oNlLJuTKuNSS7uhbCgVUdWAAYBKAFlMoKKZuhRuEMqoFaU7fW4gaGogcCol6s2LtD7nbZTOQshTmZUW-Tn0z6raPx-v4m-O_6Ku60BKFEK0rA-hCw8fE_Afc3Nk56z1bv2RalC_qS8uq2Roo_F8qznny2NI4HlhobUfei7zpZrC__sl7HJYUCae_qEJum4FgxOLhsijknGo6NEPT-_P_q8OIuiuOHP_cWN24Lq-s</recordid><startdate>20140522</startdate><enddate>20140522</enddate><creator>Sneyd, Mary Jane</creator><creator>Cameron, Claire</creator><creator>Cox, Brian</creator><general>BioMed Central</general><general>BioMed Central Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20140522</creationdate><title>Individual risk of cutaneous melanoma in New Zealand: developing a clinical prediction aid</title><author>Sneyd, Mary Jane ; Cameron, Claire ; Cox, Brian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b484t-ad6ae472233d0c870c000f301c0148c3445f213da18fe6a26cc1b0ffe6fe0ee93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Case-Control Studies</topic><topic>Chi-Square Distribution</topic><topic>Decision Support Techniques</topic><topic>Epidemiology</topic><topic>Ethics</topic><topic>Female</topic><topic>Genetic Predisposition to Disease</topic><topic>Genotype &amp; phenotype</topic><topic>Humans</topic><topic>Incidence</topic><topic>Interviews</topic><topic>Laboratories</topic><topic>Logistic Models</topic><topic>Male</topic><topic>Medicine</topic><topic>Melanoma</topic><topic>Melanoma - diagnosis</topic><topic>Melanoma - epidemiology</topic><topic>Melanoma - genetics</topic><topic>Middle Aged</topic><topic>Missing data</topic><topic>Mortality</topic><topic>Multivariate Analysis</topic><topic>Nevus - diagnosis</topic><topic>Nevus - epidemiology</topic><topic>Nevus - genetics</topic><topic>New Zealand - epidemiology</topic><topic>Population</topic><topic>Predictive Value of Tests</topic><topic>Prevention</topic><topic>Residence Characteristics</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Scandals</topic><topic>Sex Factors</topic><topic>Skin cancer</topic><topic>Skin Neoplasms - diagnosis</topic><topic>Skin Neoplasms - epidemiology</topic><topic>Skin Neoplasms - genetics</topic><topic>Skin Pigmentation</topic><topic>Time Factors</topic><topic>Variables</topic><topic>Women</topic><topic>Workplace</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sneyd, Mary Jane</creatorcontrib><creatorcontrib>Cameron, Claire</creatorcontrib><creatorcontrib>Cox, Brian</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMC cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sneyd, Mary Jane</au><au>Cameron, Claire</au><au>Cox, Brian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Individual risk of cutaneous melanoma in New Zealand: developing a clinical prediction aid</atitle><jtitle>BMC cancer</jtitle><addtitle>BMC Cancer</addtitle><date>2014-05-22</date><risdate>2014</risdate><volume>14</volume><issue>1</issue><spage>359</spage><epage>359</epage><pages>359-359</pages><artnum>359</artnum><issn>1471-2407</issn><eissn>1471-2407</eissn><abstract>New Zealand and Australia have the highest melanoma incidence rates worldwide. In New Zealand, both the incidence and thickness have been increasing. Clinical decisions require accurate risk prediction but a simple list of genetic, phenotypic and behavioural risk factors is inadequate to estimate individual risk as the risk factors for melanoma have complex interactions. In order to offer tailored clinical management strategies, we developed a New Zealand prediction model to estimate individual 5-year absolute risk of melanoma. A population-based case-control study (368 cases and 270 controls) of melanoma risk factors provided estimates of relative risks for fair-skinned New Zealanders aged 20-79 years. Model selection techniques and multivariate logistic regression were used to determine the important predictors. The relative risks for predictors were combined with baseline melanoma incidence rates and non-melanoma mortality rates to calculate individual probabilities of developing melanoma within 5 years. For women, the best model included skin colour, number of moles &gt; =5 mm on the right arm, having a 1st degree relative with large moles, and a personal history of non-melanoma skin cancer (NMSC). The model correctly classified 68% of participants; the C-statistic was 0.74. For men, the best model included age, place of occupation up to age 18 years, number of moles &gt; =5 mm on the right arm, birthplace, and a history of NMSC. The model correctly classified 67% of cases; the C-statistic was 0.71. We have developed the first New Zealand risk prediction model that calculates individual absolute 5-year risk of melanoma. This model will aid physicians to identify individuals at high risk, allowing them to individually target surveillance and other management strategies, and thereby reduce the high melanoma burden in New Zealand.</abstract><cop>England</cop><pub>BioMed Central</pub><pmid>24884419</pmid><doi>10.1186/1471-2407-14-359</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1471-2407
ispartof BMC cancer, 2014-05, Vol.14 (1), p.359-359, Article 359
issn 1471-2407
1471-2407
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4038363
source MEDLINE; DOAJ Directory of Open Access Journals; SpringerLink Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access; Springer Nature OA Free Journals
subjects Adult
Aged
Case-Control Studies
Chi-Square Distribution
Decision Support Techniques
Epidemiology
Ethics
Female
Genetic Predisposition to Disease
Genotype & phenotype
Humans
Incidence
Interviews
Laboratories
Logistic Models
Male
Medicine
Melanoma
Melanoma - diagnosis
Melanoma - epidemiology
Melanoma - genetics
Middle Aged
Missing data
Mortality
Multivariate Analysis
Nevus - diagnosis
Nevus - epidemiology
Nevus - genetics
New Zealand - epidemiology
Population
Predictive Value of Tests
Prevention
Residence Characteristics
Risk Assessment
Risk Factors
Scandals
Sex Factors
Skin cancer
Skin Neoplasms - diagnosis
Skin Neoplasms - epidemiology
Skin Neoplasms - genetics
Skin Pigmentation
Time Factors
Variables
Women
Workplace
Young Adult
title Individual risk of cutaneous melanoma in New Zealand: developing a clinical prediction aid
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T15%3A16%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Individual%20risk%20of%20cutaneous%20melanoma%20in%20New%20Zealand:%20developing%20a%20clinical%20prediction%20aid&rft.jtitle=BMC%20cancer&rft.au=Sneyd,%20Mary%20Jane&rft.date=2014-05-22&rft.volume=14&rft.issue=1&rft.spage=359&rft.epage=359&rft.pages=359-359&rft.artnum=359&rft.issn=1471-2407&rft.eissn=1471-2407&rft_id=info:doi/10.1186/1471-2407-14-359&rft_dat=%3Cproquest_pubme%3E1532939774%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1537115522&rft_id=info:pmid/24884419&rfr_iscdi=true